Oncology

Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Condition:   Stage IV Non-small Cell Lung Cancer
Interventions:   Drug: Pembrolizumab;   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Rucaparib
Sponsors:   University of Michigan Cancer Center;   Merck Sharp & Dohme Corp.;   Clovis Oncology, Inc.
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 16, 2018 / by / in
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

Conditions:   Carcinoma, Small Cell;   Lung Cancer;   Small Cell Lung Cancer
Interventions:   Drug: M7824 (Arm A/B);   Drug: Topotecan;   Drug: Temozolomide
Sponsor:   National Cancer Institute (NCI)
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 13, 2018 / by / in
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal Cancer

Condition:   Resectable Esophageal Cancer
Interventions:   Combination Product: Avelumab combined with Chemoradiation;   Drug: Carboplatin;   Drug: Paclitaxel;   Radiation: Radiation
Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 12, 2018 / by / in
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Conditions:   BRCA1 Gene Mutation;   BRCA2 Gene Mutation;   Folate Receptor Alpha Positive;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Uterine Serous Carcinoma;   Recurrent Uterine Carcinosarcoma;   Platinum Resistant Ovarian Cancer
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Mirvetuximab Soravtansine;   Other: Pharmacokinetic Study;   Drug: Rucaparib Camsylate
Sponsors:   Ohio State University Comprehensive Cancer Center;   ImmunoGen, Inc.;   Clovis Oncology, Inc.
Not yet recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 11, 2018 / by / in
Exercise Intervention After Cancer Treatment for Improving Health in Stage II-III Breast Cancer Survivors

Conditions:   Anatomic Stage II Breast Cancer AJCC v8;   Anatomic Stage IIA Breast Cancer AJCC v8;   Anatomic Stage IIB Breast Cancer AJCC v8;   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Cancer Survivor;   Estrogen Receptor Positive;   HER2/Neu Negative;   Progesterone Receptor Positive;   Prognostic Stage II Breast Cancer AJCC v8;   Prognostic Stage IIA Breast Cancer AJCC v8;   Prognostic Stage IIB Breast Cancer AJCC v8;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Sedentary Lifestyle
Interventions:   Behavioral: Exercise Intervention;   Other: Informational Intervention;   Other: Laboratory Biomarker Analysis;   Device: Monitoring Device;   Other: Questionnaire Administration;   Other: Physical Performance Testing
Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 10, 2018 / by / in
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

Conditions:   Stage I Lung Cancer;   Stage I Non-Small Cell Lung Cancer AJCC v7;   Stage IA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IB Non-Small Cell Lung Carcinoma AJCC v7;   Stage II Lung Cancer;   Stage II Non-Small Cell Lung Cancer AJCC v7;   Stage IIA Non-Small Cell Lung Carcinoma AJCC v7;   Stage IIB Non-Small Cell Lung Carcinoma AJCC v7
Interventions:   Drug: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography (PET);   Radiation: Stereotactic Body Radiation Therapy (SBRT)
Sponsors:   Emory University;   RefleXion Medical
Recruiting
ClinicalTrials.gov: Oncology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

June 9, 2018 / by / in